Rhumbline Advisers Adaptive Biotechnologies Corp Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Rhumbline Advisers holds 175,841 shares of ADPT stock, worth $998,776. This represents 0.0% of its overall portfolio holdings.

Number of Shares
175,841
Previous 188,285 6.61%
Holding current value
$998,776
Previous $681,000 32.16%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$3.37 - $5.12 $41,936 - $63,713
-12,444 Reduced 6.61%
175,841 $900,000
Q2 2024

Aug 01, 2024
BUY
$2.34 - $3.96 $33,766 - $57,142
14,430 Added 8.3%
188,285 $681,000
Q1 2024

May 09, 2024
BUY
$2.88 - $4.8 $12,355 - $20,592
4,290 Added 2.53%
173,855 $558,000
Q4 2023

Feb 08, 2024
BUY
$3.46 - $5.33 $32,337 - $49,814
9,346 Added 5.83%
169,565 $830,000
Q3 2023

Nov 09, 2023
BUY
$5.07 - $8.44 $15,052 - $25,058
2,969 Added 1.89%
160,219 $873,000
Q2 2023

Aug 08, 2023
SELL
$6.19 - $8.78 $129,661 - $183,914
-20,947 Reduced 11.75%
157,250 $1.06 Million
Q1 2023

May 11, 2023
BUY
$7.8 - $10.11 $48,227 - $62,510
6,183 Added 3.59%
178,197 $1.57 Million
Q4 2022

Feb 14, 2023
BUY
$6.26 - $9.34 $9,703 - $14,477
1,550 Added 0.91%
172,014 $1.31 Million
Q3 2022

Nov 10, 2022
BUY
$6.5 - $12.67 $65,591 - $127,852
10,091 Added 6.29%
170,464 $1.21 Million
Q2 2022

Aug 11, 2022
BUY
$6.4 - $14.73 $410,374 - $944,502
64,121 Added 66.62%
160,373 $1.3 Million
Q1 2022

May 12, 2022
SELL
$10.12 - $28.9 $70,597 - $201,606
-6,976 Reduced 6.76%
96,252 $1.34 Million
Q4 2021

Feb 10, 2022
BUY
$25.17 - $36.85 $119,280 - $174,632
4,739 Added 4.81%
103,228 $2.9 Million
Q3 2021

Nov 12, 2021
SELL
$30.02 - $39.87 $39,896 - $52,987
-1,329 Reduced 1.33%
98,489 $3.35 Million
Q2 2021

Aug 05, 2021
BUY
$32.22 - $44.59 $745,441 - $1.03 Million
23,136 Added 30.17%
99,818 $4.08 Million
Q1 2021

May 06, 2021
SELL
$37.26 - $67.74 $344,505 - $626,324
-9,246 Reduced 10.76%
76,682 $3.09 Million
Q4 2020

Feb 10, 2021
BUY
$45.01 - $65.47 $86,779 - $126,226
1,928 Added 2.3%
85,928 $5.08 Million
Q3 2020

Nov 12, 2020
BUY
$35.79 - $48.81 $135,107 - $184,257
3,775 Added 4.71%
84,000 $4.09 Million
Q2 2020

Aug 13, 2020
BUY
$24.95 - $48.38 $503,466 - $976,260
20,179 Added 33.61%
80,225 $3.88 Million
Q1 2020

May 06, 2020
BUY
$16.96 - $34.16 $752,786 - $1.52 Million
44,386 Added 283.44%
60,046 $1.67 Million
Q4 2019

Feb 05, 2020
BUY
$24.56 - $32.8 $105,386 - $140,744
4,291 Added 37.74%
15,660 $469,000
Q3 2019

Oct 23, 2019
BUY
$30.31 - $53.51 $344,594 - $608,355
11,369 New
11,369 $351,000

Others Institutions Holding ADPT

# of Institutions
202
Shares Held
146M
Call Options Held
68.8K
Put Options Held
42.5K
View Full List

About Adaptive Biotechnologies Corp

ADPT Quotes by TradingView
  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $812M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email